Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label studyMyrthe J. van Dijk, Eduard J. van Beers, Minke A.E. Rab et al.|American Journal of Hematology|2022Cited by 45
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label studyMyrthe J. van Dijk, Eduard J. van Beers, Minke A.E. Rab et al.|Blood Advances|2023Cited by 32
Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell diseaseMyrthe J. van Dijk, Richard van Wijk, Titine Ruiter et al.|HemaSphere|2024Cited by 14
Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator MitapivatMyrthe J. van Dijk, Eduard J. van Beers, Sigrid van der Veen et al.|Blood|2022Cited by 2
P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASEMyrthe van Dijk, Eduard J. van Beers, Brigitte van Oirschot et al.|HemaSphere|2023Cited by 0